Future studies with larger sample sizes, randomized controlled designs, dose-response analyses, multivariate adjustments, and subgroup evaluations are essential to address these limitations
Kutcher AM, LeBaron VT
Semaglutide delivers significant weight loss averaging 15-17% of body weight, improved cardiovascular health markers, enhanced glycemic control, reduced appetite, and sustained weight maintenance over extended periods
Researchers also observed improvements in several metabolic health markers, including blood pressure, cholesterol levels and insulin sensitivity
Furthermore, GLP- 1R-positive cases showed statistically significantly higher expression of insulin and proinsulin than GLP- 1R negative cases, so GLP- 1R could be associated with insulin production in PanNETs like cells in pancreatic islets [8]